Evidence map›Paper›PMID 39145167›Full record

ArticleFrontiers in public health2024

Negligence in biomedical research: an anti-racist approach for substance use researchers.

Jonathan Lehman, Danniella Balangoy, Angie P Mejia, Carlos Cardenas-Iniguez, Scott Marek, Anita C Randolph

Abstract read
In one paragraph

Article in Frontiers in public health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jonathan Lehman *Masonic Institute for the Developing Brain, University of Minnesota, Minneapolis, MN, United States.
Danniella Balangoy *Masonic Institute for the Developing Brain, University of Minnesota, Minneapolis, MN, United States.
Angie P MejiaMasonic Institute for the Developing Brain, University of Minnesota, Minneapolis, MN, United States.
Carlos Cardenas-IniguezDepartment of Population and Public Health Sciences, University of Southern California, Los Angeles, CA, United States.
Scott MarekMallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, United States.
Anita C RandolphMasonic Institute for the Developing Brain, University of Minnesota, Minneapolis, MN, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Racism is embedded in the fabric of society at structural, disciplinary, hegemonic, and interpersonal levels, working as a mechanism that drives health disparities. In particular, stigmatized views of substance use get entangled with racialization, serving as a tool to uphold oppressive systems. While national health institutions have made commitments to dismantle these systems in the United States, anti-racism has not been integrated into biomedical research practice. The ways in which substance use researchers use and interpret race data-without engaging in structural racism as a mechanism of health inequity-can only be described as inadequate. Drawing upon concepts from the Public Health Critical Race praxis, QuantCrit, and an anti-racism research framework, we recommend a set of guidelines to help biomedical researchers conceptualize and engage with race more responsibly in substance use research.

Indexed as

Biomedical ResearchSubstance-Related DisordersSystemic RacismHealthcare DisparitiesHumansMalpracticeSocial Stigmaantiracismcritical race theory (CRT)equityJ-DEIracializationracismresearchsubstance use

Identifiers

PMID39145167
PMCPMC11322128

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.